Risk of Clostridium difficile - Associated disease among patients receiving proton-pump inhibitors in a Quebec Medical Intensive Care Unit

Infection Control and Hospital Epidemiology

Volumn 28, Issue 11, 2007, Pages 1305-1307

  Beaulieu, Mathieu ^a   Williamson, David ^a,b   Pichette, Gilbert ^b   Lachaine, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; PENICILLIN G; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

AGED; ARTICLE; BACTERIAL INFECTION; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; FEMALE; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; APACHE; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; PROTON PUMPS; QUEBEC; RISK FACTORS;

EID: 35349004070     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/521664     Document Type: Article

References (11)

1. Centers for Disease Control and Prevention. Data and statistics about Clostridium difficile infections. Available at: http://www.cdc.gov/ ncidod/dhqp/id_Cdiff_data.html. Accessed June 27, 2007.
2. Pindera L. C. difficile inquest too narrow as "Quebec strain" goes international. CMAJ 2007; 176:915-916.
3. Eggertson L, Sibbald B. Hospitals battling outbreaks of C. difficile. CMAJ 2004; 171:19-21.
4. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007; 28:198-201.
5. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-9.
6. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006; 166:2518-2524.
7. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-280.
8. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260.
9. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea in hospital in-patients prescribed proton-pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-38.
10. Lozniewski A, Rabaud C, Dotto E, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001; 39:1996-1998.
11. Cook SF, Visscher WA, Hobbs CL, Williams RL. Project IMPACT: results from a pilot validity study of a new observational database. Crit Care Med 2002; 30:2765-2770.